Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E. Shaw AT, et al. Among authors: viraswami appanna k. Lancet Oncol. 2017 Jul;18(7):874-886. doi: 10.1016/S1470-2045(17)30339-X. Epub 2017 Jun 9. Lancet Oncol. 2017. PMID: 28602779 Clinical Trial.
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC.
Nishio M, Felip E, Orlov S, Park K, Yu CJ, Tsai CM, Cobo M, McKeage M, Su WC, Mok T, Scagliotti GV, Spigel DR, Viraswami-Appanna K, Chen Z, Passos VQ, Shaw AT. Nishio M, et al. Among authors: viraswami appanna k. J Thorac Oncol. 2020 Apr;15(4):609-617. doi: 10.1016/j.jtho.2019.11.006. Epub 2019 Nov 25. J Thorac Oncol. 2020. PMID: 31778798 Free article. Clinical Trial.
Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.
Cho BC, Obermannova R, Bearz A, McKeage M, Kim DW, Batra U, Borra G, Orlov S, Kim SW, Geater SL, Postmus PE, Laurie SA, Park K, Yang CT, Ardizzoni A, Bettini AC, de Castro G Jr, Kiertsman F, Chen Z, Lau YY, Viraswami-Appanna K, Passos VQ, Dziadziuszko R. Cho BC, et al. Among authors: viraswami appanna k. J Thorac Oncol. 2019 Jul;14(7):1255-1265. doi: 10.1016/j.jtho.2019.03.002. Epub 2019 Mar 7. J Thorac Oncol. 2019. PMID: 30851442 Free article. Clinical Trial.
Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.
Lau YY, Gu W, Lin T, Viraswami-Appanna K, Cai C, Scott JW, Shi M. Lau YY, et al. Among authors: viraswami appanna k. Cancer Chemother Pharmacol. 2017 Jun;79(6):1119-1128. doi: 10.1007/s00280-017-3308-7. Epub 2017 Apr 19. Cancer Chemother Pharmacol. 2017. PMID: 28424965 Clinical Trial.
Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial.
Melichar B, Casado E, Bridgewater J, Bennouna J, Campone M, Vitek P, Delord JP, Cerman J Jr, Salazar R, Dvorak J, Sguotti C, Urban P, Viraswami-Appanna K, Tan E, Tabernero J. Melichar B, et al. Among authors: viraswami appanna k. Br J Cancer. 2011 Nov 22;105(11):1646-53. doi: 10.1038/bjc.2011.438. Epub 2011 Oct 25. Br J Cancer. 2011. PMID: 22027708 Free PMC article. Clinical Trial.
Accelerating drug development at Bristol Myers Squibb through innovation.
Viraswami-Appanna K, Buenconsejo J, Baidoo C, Chan I, Li D, Micsinai-Balan M, Tiwari R, Yang L, Sethuraman V. Viraswami-Appanna K, et al. Drug Discov Today. 2024 May;29(5):103952. doi: 10.1016/j.drudis.2024.103952. Epub 2024 Mar 18. Drug Discov Today. 2024. PMID: 38508230